

Haematologica
HAEMATOL/2019/232330
Version 2

Venetoclax in combination with carfilzomib, doxorubicin and dexamethasone restores responsiveness in an otherwise treatment-refractory multiple myeloma patient

Sarolta Bojtine Kovacs, Jingting Luan, Sandra Maria Dold, Andreas Weis, Milena Pantic, Justus Duyster, Ralph Wäsch, and Monika Engelhardt

Disclosures: SBK, JL, SMD, AW and MP have no financial or other relationships that might lead to a conflict of interest. RW has received research and travel support from Sanofi, Gilead, Jazz, Celgene and Amgen, and has received consultancy fees from Sanofi, Pfizer, Gilead, Novartis, Amgen and Takeda. ME has received educational and trial support from Amgen, Celgene, Takeda, BMS, Janssen, Novartis, Karyopharm, and has received honoraria and consultancy fees from BMS, Celgene, Amgen, Takeda, Novartis and Janssen. This paper has successfully passed the internal review process in our institution.

Contributions: All contributing authors have directly participated in the analysis of the data, patient care and have approved the final version of the manuscript. SBK, JL and ME wrote the paper.